162 related articles for article (PubMed ID: 8027981)
21. Characterisation, CNS distribution and function of NK2 receptors studied using potent NK2 receptor antagonists.
Hagan RM; Beresford IJ; Stables J; Dupere J; Stubbs CM; Elliott PJ; Sheldrick RL; Chollet A; Kawashima E; McElroy AB
Regul Pept; 1993 Jul; 46(1-2):9-19. PubMed ID: 8210508
[No Abstract] [Full Text] [Related]
22. Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan.
Rivier J; Erchegyi J; Hoeger C; Miller C; Low W; Wenger S; Waser B; Schaer JC; Reubi JC
J Med Chem; 2003 Dec; 46(26):5579-86. PubMed ID: 14667212
[TBL] [Abstract][Full Text] [Related]
23. Effect of scyliorhinin I and synthetic scyliorhinin I derivatives at mammalian tachykinin NK1, NK2 and NK3 receptors.
Patacchini R; Quartara L; Rolka K; Zboinska J; Kupryszewski G; Maggi CA
Eur J Pharmacol; 1993 Dec; 250(2):311-6. PubMed ID: 7509285
[TBL] [Abstract][Full Text] [Related]
24. A high throughput fluorogenic substrate for stromelysin (MMP-3).
Bickett DM; Green MD; Wagner C; Roth JT; Berman J; McGeehan GM
Ann N Y Acad Sci; 1994 Sep; 732():351-5. PubMed ID: 7978805
[TBL] [Abstract][Full Text] [Related]
25. A new series of photoactivatable and iodinatable linear vasopressin antagonists.
Carnazzi E; Aumelas A; Barberis C; Guillon G; Seyer R
J Med Chem; 1994 Jun; 37(12):1841-9. PubMed ID: 8021923
[TBL] [Abstract][Full Text] [Related]
26. Identification of both NK1 and NK2 receptors in guinea-pig airways.
McKee KT; Millar L; Rodger IW; Metters KM
Br J Pharmacol; 1993 Oct; 110(2):693-700. PubMed ID: 7694756
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the [125I]-neurokinin A binding site in the circular muscle of human colon.
Warner FJ; Comis A; Miller RC; Burcher E
Br J Pharmacol; 1999 Jul; 127(5):1105-10. PubMed ID: 10455255
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological characterization of tachykinin-induced intracellular calcium rise in a human NK2 receptor transfected cell line.
Subramanian N; Ruesch C; Bertrand C
Biochem Biophys Res Commun; 1994 May; 200(3):1512-20. PubMed ID: 8185607
[TBL] [Abstract][Full Text] [Related]
29. A family of depsi-peptide fungal metabolites, as selective and competitive human tachykinin receptor (NK2) antagonists: fermentation, isolation, physico-chemical properties, and biological activity.
Hedge VR; Puar MS; Dai P; Pu H; Patel M; Anthes JC; Richard C; Terracciano J; Das PR; Gullo V
J Antibiot (Tokyo); 2001 Feb; 54(2):125-35. PubMed ID: 11302484
[TBL] [Abstract][Full Text] [Related]
30. Fluorescent labeling of NK2 receptor at specific sites in vivo and fluorescence energy transfer analysis of NK2 ligand-receptor complexes.
Turcatti G; Nemeth K; Edgerton MD; Knowles J; Vogel H; Chollet A
Recept Channels; 1997; 5(3-4):201-7. PubMed ID: 9606724
[TBL] [Abstract][Full Text] [Related]
31. Probing the binding domain of the Saccharomyces cerevisiae alpha-mating factor receptor with rluorescent ligands.
Ding FX; Lee BK; Hauser M; Davenport L; Becker JM; Naider F
Biochemistry; 2001 Jan; 40(4):1102-8. PubMed ID: 11170434
[TBL] [Abstract][Full Text] [Related]
32. NK2 receptor-mediated spontaneous phasic contractions in normal and ulcerative colitis human sigmoid colon.
Cao W; Harnett KM; Pricolo VE
J Pharmacol Exp Ther; 2006 Jun; 317(3):1349-55. PubMed ID: 16554357
[TBL] [Abstract][Full Text] [Related]
33. Affinity, potency, efficacy, and selectivity of neurokinin A analogs at human recombinant NK2 and NK1 receptors.
Rupniak NMJ; Perdona E; Griffante C; Cavallini P; Sava A; Ricca DJ; Thor KB; Burgard EC; Corsi M
PLoS One; 2018; 13(10):e0205894. PubMed ID: 30359406
[TBL] [Abstract][Full Text] [Related]
34. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
[TBL] [Abstract][Full Text] [Related]
35. Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands.
Wilczynski A; Wang XS; Joseph CG; Xiang Z; Bauzo RM; Scott JW; Sorensen NB; Shaw AM; Millard WJ; Richards NG; Haskell-Luevano C
J Med Chem; 2004 Apr; 47(9):2194-207. PubMed ID: 15084118
[TBL] [Abstract][Full Text] [Related]
36. Agonist properties of putative small-molecule somatostatin sst2 receptor-selective antagonists.
Nunn C; Langenegger D; Hurth K; Schmidt K; Fehlmann D; Hoyer D
Eur J Pharmacol; 2003 Apr; 465(3):211-8. PubMed ID: 12681432
[TBL] [Abstract][Full Text] [Related]
37. An investigation of tachykinin NK2 receptor subtypes in the rat.
Matuszek MA; Zeng XP; Strigas J; Burcher E
Eur J Pharmacol; 1998 Jul; 352(1):103-9. PubMed ID: 9718274
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo pharmacology of S 16474, a novel dual tachykinin NK1 and NK2 receptor antagonist.
Robineau P; Lonchampt M; Kucharczyk N; Krause JE; Regoli D; Fauchere JL; Prost JF; Canet E
Eur J Pharmacol; 1995 Dec; 294(2-3):677-84. PubMed ID: 8750733
[TBL] [Abstract][Full Text] [Related]
39. Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.
Erchegyi J; Waser B; Schaer JC; Cescato R; Brazeau JF; Rivier J; Reubi JC
J Med Chem; 2003 Dec; 46(26):5597-605. PubMed ID: 14667214
[TBL] [Abstract][Full Text] [Related]
40. A flexible approach to the design of new potent substance P receptor ligands.
Millet R; Goossens L; Bertrand-Caumont K; Goossens JF; Houssin R; Hénichart JP
J Pharm Pharmacol; 2001 Jul; 53(7):929-34. PubMed ID: 11480541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
